Batavia Biosciences focuses on accelerating transition of biopharmaceutical product candidates from discovery to clinic with improved success and lower cost.
PRESS RELEASE: Batavia announces that we’ve teamed up with Veeva to further optimize our global quality assurance with Veeva Vault Quality Suite. Batavia will benefit by unifying content, processes, and training management all on a single platform.
bataviabiosciences.com/batav…
In a MAJOR development, Batavia Biosciences is proud to announce that we will be entering the commercial manufacturing business. We will be opening a state-of-the-art, 12,000 square meter facility in Leiden, The Netherlands.
bataviabiosciences.com/batav…#Bioprocessing#globalhealth
Today, Batavia Biosciences announces the expansion of its headquarters and R&D capacities by another 22,500 sq. ft. This expansion will aid in our journey to meet increased global demand for vaccine development and virotherapies. Read more about it here!
bataviabiosciences.com/batav…
We can't wait for the year's premier vaccine event, @vaccinenation, where our own Director of Operations will be offering his insight into adenovirus vectored vaccines. Come discuss opportunities to bring your vaccine candidate from bench to clinic! #WVCDCbataviabiosciences.com/world…
#Adenovirus vectors have an impressive track record and are used in some of the most high-profile clinical trials in the field of #genetherapy, and have been approved as vaccine carriers to battle COVID-19. Check out the 1st of our 3-part series here!
bataviabiosciences.com/past-…
We’re joining @NIIMBL! As a member, we continue to work towards accelerating biopharmaceutical innovation, facilitating development of industry standards, and supporting access to a world leading biopharmaceutical workforce.
#bioprocessing#CDMObataviabiosciences.com/batav…
Introducing the new #LEAP4WA website – a one stop shop where you can learn about this innovative, international collaboration that is advancing an effective vaccine to prevent #Lassafever in West Africa.🌍
🔗Learn more at LEAP4WA.org
We wish you and your loved ones a safe, and joyous #holidayseason. While this year has had its challenges, it also highlighted what is truly important: #wellbeing, #lovedones and the precious time spent together. Let’s strive to bring smiles on people’s faces in 2022.
Through an innovative partnership model among @IAVI, @CEPIvaccines, & an expert consortium of collaborators, we plan to further support the development of IAVI’s Lassa fever vaccine candidate with our HIP-Vax platform.
#bioprocessing#CDMO#vectorvaccines
We've launched the largest ever #Lassafever study in West Africa to provide a more accurate assessment on the disease burden in the region🌍
Up to 23,000 participants will take part in Benin 🇧🇯, Guinea🇬🇳, Liberia🇱🇷, Sierra Leone 🇸🇱 and Nigeria🇳🇬
bit.ly/3xc1kmX
We have successfully manufactured clinical trial material using HIP-Vax! We produced @IAVI's #Lassavaccine candidate for Phase I. HIP-Vax uses the novel fixed-bed bioreactor, scale-X. This is the first clinical batch ever produced on a scale-X system.
bataviabiosciences.com/news/…
We're proud to announce our collaboration with RocketVax, a subsidiary of Swiss Rockets. Batavia will develop the clinical process and deliver clinical product of RocketVax’s highly promising second generation SARS-CoV-2 vaccine candidate.
#covid19vaccine#bioprocessing#CDMO